# Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

> **NCT03145181** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 302 (actual)

## Conditions studied

- Hematological Malignancies

## Interventions

- **DRUG:** Teclistamab (IV)
- **DRUG:** Teclistamab(SC)

## Key facts

- **NCT ID:** NCT03145181
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-05-16
- **Primary completion:** 2025-09-25
- **Final completion:** 2027-05-28
- **Target enrollment:** 302 (ACTUAL)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03145181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03145181, "Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03145181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*